Roxbury Financial LLC Decreases Stock Position in Pfizer Inc. $PFE

Roxbury Financial LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 30.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,946 shares of the biopharmaceutical company’s stock after selling 3,481 shares during the quarter. Roxbury Financial LLC’s holdings in Pfizer were worth $193,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Gould Capital LLC boosted its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 3.8%

Shares of PFE opened at $23.91 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock’s 50 day moving average is $24.79 and its two-hundred day moving average is $24.28. The firm has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Finally, Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.